5th Dry AMD and GA Therapeutics Summit

Memo

The surge of ground-breaking updates in Geographic Atrophy, along with significant advancements in developing robust biomarkers and functional endpoints, has ignited a wave of innovation in the field of ophthalmic drug development. The 5th Dry AMD and GA Therapeutics Summit will unite 80+ biopharma stakeholders, from discovery to early clinical development, across three days of focused discussion. This summit is the definitive forum for KOLs, industry experts, and regulators to drive the next generation of dry AMD and Geographic Atrophy therapeutics forward. Join us to explore the latest in preclinical models, optimize trial strategies, and overcome safety and regulatory challenges to supercharge your pipeline. URLs:Tickets: https://go.evvnt.com/2621490-2?pid=5569 Brochure: https://go.evvnt.com/2621490-3?pid=5569  Date and Time: On Mon, 28 Oct 2024 09:00 - Wed, 30 Oct 2024 17:00 Venue Details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States Prices:Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,Drug Developer Pricing - Conference Only: USD 2999.00,Academic Pricing - Conference + Workshop Day: USD 3597.00,Academic Pricing - Conference Only: USD 2599.00,Solution Provider Pricing - Conference + Workshop Day: USD 5097.00,Solution Provider Pricing - Conference Only: USD 3699.00 Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Anitha Krishnan, Executive Director - Research, Aviceda Therapeutics, Anneke Hollander, Head of Cellular Genomics, Genome Biology and Functional Genomics, Abbvie, Brian Levy, CEO, Ocunexus Therapeutics, Christine Curcio, Ophthalmology and Visual Sciences Professor, University of Alabama at Birmingham, Cynthia Tung, Medical Director Ophthalmology, Boehringer Ingelheim, Daniela Ferrara, Principal Medical Director, Genentech, David Zacks, Chief Scientific Officer/Chief Medical Officer, ONL Therapeutics, Deepayan Kar, Biomarker Scientist, Apellis Pharmaceuticals, Dennis Giesing, Translational Medicine Consultant, GelMEDIX, Fnu Ruchi, Scientist, National Eye Institute, Harshal Shah, Head of Device Strategy and Innovation, Sanofi, Justin Creel, Head Of Targeted Therapeutics Delivery Center, Novartis, Nehal Mehta, Chief Executive Officer, Mobius Scientific, Peter de Haan, Chief Scientific Officer and Co-founder, Amarna Therapeutics, Rajesh Rao, Ophthalmology and Visual Sciences Professor, University of Michigan, Samarendra Mohanty, Chief Scientific Officer, Nanoscope Therapeutics, Samuel Lessard, Principal Genetics Scientist, Sanofi, Vicken Karageozian, Chief Executive Officer, Allegro Ophthalmics